These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
    Author: Thys B, De Palma AM, Neyts J, Andries K, Vrijsen R, Rombaut B.
    Journal: Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707.
    Abstract:
    In this study the antiviral activity of a panel of 18 out of 240 pyridazinamine analogues was evaluated against the Sabin strains of the three poliovirus types. We found one compound, R75761 which had a comparable 50% effective concentration (EC50) value against all three poliovirus Sabin strains. Virus multiplication was reduced by 10(4.0)-fold, 10(6.2)-fold and 10(6.6)-fold for poliovirus type 1, type 2 and type 3, respectively. R75761 could be considered as a lead compound for development of anti-poliovirus drugs to be used during the late stage of poliovirus eradication and beyond.
    [Abstract] [Full Text] [Related] [New Search]